Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc (Mereo) is dated July 15, 2019. Mereo is a clinical-stage biopharmaceutical company focused on rare diseases. The filing primarily announces a successful Type B meeting with the U.S. FDA regarding navicixizumab, a product candidate acquired through the April 2019 merger with OncoMed Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. As a clinical-stage company, the document focuses exclusively on clinical development milestones and regulatory progress rather than financial performance metrics.
Material Changes and Clinical Progress
- Regulatory Milestone: Mereo and the FDA agreed in principle on the design of a Phase 2 clinical trial for navicixizumab in advanced ovarian cancer, which could support accelerated approval.
- Study Design: The proposed Phase 2 trial will target patients with platinum-resistant ovarian cancer who have failed prior therapies. The primary endpoint is confirmed overall response rate (ORR).
- Phase 1b Data: In the ongoing Phase 1b study (navicixizumab plus paclitaxel), 44 patients were enrolled. As of the Q1 2019 data cut, the unconfirmed ORR was 41% (18/44). The median progression-free survival (PFS) was 7.3 months.
- Subgroup Analysis: The unconfirmed ORR was 64% for bevacizumab-naive patients and 30% for bevacizumab pre-treated patients.
- Safety Profile: Common adverse events included hypertension (68%), fatigue (46%), and headache (25%). No Grade 3 pulmonary hypertension cases were reported.
Guidance, Outlook, and Risks
Outlook and Strategy: Management indicated that partnering discussions for navicixizumab have commenced, aligning with the corporate strategy to focus on the rare disease portfolio. The company expects top-line 12-month blinded data for setrusumab (osteogenesis imperfecta) in Q4 2019 and data from the alvelestat Phase 2 trial around the end of 2019.
Risks and Contingencies:
- Immunogenicity: Treatment-induced anti-drug antibody (ADA) formation occurred in 17% of subjects in the Phase 1a trial. In 3 of these 5 subjects, accelerated clearance and decreased exposure were evident, with two experiencing infusion reactions.
- Safety Events: Notable adverse events included one Grade 1 heart failure, one Grade 3 and one Grade 4 thrombocytopenia, and one Grade 4 gastrointestinal perforation.
- Development Risk: As a clinical-stage company, Mereo relies on successful trial outcomes and potential partnerships for future funding and commercialization.
Investor Verification Checklist
- Verify the final agreement on the Phase 2 trial design with the FDA following the Type B meeting.
- Monitor the status and outcome of the partnering discussions for navicixizumab.
- Review upcoming data releases for setrusumab (Q4 2019) and alvelestat (end of 2019).
- Assess the long-term impact of the observed immunogenicity (ADA formation) on navicixizumab efficacy and safety in larger trials.
- Check subsequent filings for cash runway and capital raise activities, as this filing does not disclose liquidity status.